- Company to host webcast on Tuesday,
March 5, 2024 at 8:30 a.m.
EST
- Interim clinical data will be presented by Aravindhan
Veerapandiyan, M.D., primary investigator of the AFFINITY DUCHENNE
trial, at the MDA Clinical & Scientific Conference on
Wednesday, March 6, 2024 at 12:00
p.m. EST
ROCKVILLE, Md., Feb. 29,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a live webcast to discuss new
interim clinical data from the Phase I/II AFFINITY
DUCHENNE® trial of RGX-202 for the treatment of Duchenne
muscular dystrophy. Primary investigator Aravindhan Veerapandiyan,
M.D. will join the webcast and be available for Q&A.
Webcast details
Title: Interim Clinical Data
from Phase I/II AFFINITY DUCHENNE Trial of RGX-202
Date/Time: Tuesday, March 5, 2024, at 8:30 a.m. EST
Access: The live webcast can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available for approximately
30 days following the presentation.
Muscular Dystrophy Association Clinical &
Scientific Conference presentation details
Title:
RGX-202, an investigational gene therapy for the treatment of
Duchenne muscular dystrophy: Interim clinical data
Session: Clinical Trial Updates
Date/Time: Wednesday, March 6,
2024, 12:00 p.m. EST
Presenter: Aravindhan Veerapandiyan, M.D., Director of the
Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care
Center, and Co-Director of the Muscular Dystrophy Association Care
Center at Arkansas Children's Hospital
The presentation will be available in the Publications section
of REGENXBIO's website.
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. Since its founding
in 2009, REGENXBIO has pioneered the development of AAV
Therapeutics, an innovative class of gene therapy medicines.
REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal
and rare diseases, including ABBV-RGX-314 for the treatment of wet
AMD and diabetic retinopathy, being developed in collaboration with
AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the
treatment of MPS II. Thousands of patients have been treated with
REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA
for children with spinal muscular atrophy. Designed to be one-time
treatments, AAV Therapeutics have the potential to change the way
healthcare is delivered for millions of people. For more
information, please visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-event-to-discuss-new-interim-clinical-data-from-the-phase-iii-affinity-duchenne-trial-302076483.html
SOURCE REGENXBIO Inc.